Released Nov 2, 2023, after the close
10-Q filed Nov 2, 2023, 33 days after period end · 0000320017-23-000063
Q3 2022 · 10-Q
Revenue$0.00$0.00 — vs Q3 2021no prior Q2 2022 on file
Net Income-$5.26M-$5.26M N/M vs Q3 2021N/M vs Q2 2022
EPS Diluted-$0.65-$0.65 N/M vs Q3 2021N/M vs Q2 2022
Operating Income-$5,964,000N/M
Operating Cash Flowderived-$3,583,000N/M
Free Cash Flowderived-$3,583,000N/M
What the release said
The release
Same quarter
| Metric | Q3 2022 | Q3 2021 | Q3 2020 | Q3 2019 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | — | — |
| Net Income | -$5.26M | -$37.38M | -$6.93M | -$5.33M |
| EPS Diluted | -$0.65 | -$7.88 | -$1.74 | -$0.29 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lisata Therapeutics, Inc. · CIK 320017 · Engraved from SEC EDGAR